SCCA | Strategic Alliance Partners

Latest from SCCA


Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12, 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Parsaclisib Elicits Encouraging Response Rates in Relapsed/Refractory Follicular Lymphoma

December 17, 2021

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.

Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers

October 11, 2021

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.